Urteste SA - Asset Resilience Ratio
Urteste SA (URT) has an Asset Resilience Ratio of 10.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See URT working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Urteste SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Urteste SA's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Urteste SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Urteste SA for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł4.05 Million | 10.0% |
| Total Liquid Assets | zł4.05 Million | 10.00% |
Asset Resilience Insights
- Limited Liquidity: Urteste SA maintains only 10.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Urteste SA Industry Peers by Asset Resilience Ratio
Compare Urteste SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Urteste SA (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Urteste SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.30% | zł6.00 Million ≈ $1.65 Million |
zł45.14 Million ≈ $12.42 Million |
-17.28pp |
| 2024-12-31 | 30.59% | zł9.06 Million ≈ $2.49 Million |
zł29.62 Million ≈ $8.15 Million |
-48.85pp |
| 2023-12-31 | 79.43% | zł23.51 Million ≈ $6.47 Million |
zł29.60 Million ≈ $8.15 Million |
-- |
About Urteste SA
Urteste S.A. engages in the research and development of diagnostic tests for cancers in Poland. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.